{"title": "European Medicines Agency", "author": "EMA; COMM; DG; UNIT", "url": "https://www.ema.europa.eu/en", "hostname": "europa.eu", "description": "European Medicines Agency -", "sitename": "European Medicines Agency", "date": "2023-09-07", "cleaned_text": "- Highlights of the Safety Committee: September 2023 Highlights of the Safety Committee: September 2023 - Highlights of the Safety Committee: September 2023 Highlights of the Safety Committee: September 2023 At its monthly meeting, EMA's safety committee, the PRAC, recommended new measures to avoid topiramate exposure in pregnancy - Approval of adapted Comirnaty COVID-19 vaccine Approval of adapted Comirnaty COVID-19 vaccine - Approval of adapted Comirnaty COVID-19 vaccine Approval of adapted Comirnaty COVID-19 vaccine Adapted Comirnaty COVID-19 vaccine targets the Omicron XBB.1.5 subvariant - How EMA responded to COVID-19 How EMA responded to COVID-19 - How EMA responded to COVID-19 How EMA responded to COVID-19 EMA shares the reflections of its late former Deputy Executive Director No\u00ebl Wathion on the measures taken by EMA to fight against the COVID-19 pandemic. - Use of artificial intelligence in medicines' lifecycle Use of artificial intelligence in medicines' lifecycle - Use of artificial intelligence in medicines' lifecycle Use of artificial intelligence in medicines' lifecycle Draft reflection paper for public consultation on regulators' views on artificial intelligence for the development, use and regulation of human and veterinary medicines "}